Table 4.

Association between duration of use of antithrombotic treatment and intraplaque haemorrhage in the carotid artery

	IPH
	Model 1, OR (95% CI)	Model 2, OR (95% CI)	Model 3, OR (95% CI)
Vitamin K antagonists
Never use duration	Ref	Ref	Ref
≤3 months	0.81 (0.48–1.37)	0.76 (0.43–1.35)	1.21 (0.51–2.86)
3–11 months	1.63 (0.99–2.69)	1.62 (0.96–2.76)	2.54 (1.11–5.82)
>11 months	1.95 (1.35–2.82)	1.74 (1.16–2.60)	3.15 (1.23–8.05)
Antiplatelet agents use
Never use duration	Ref	Ref
≤30 months	1.30 (0.92–1.83)	1.14 (0.78–1.66)
30–72 months	1.54 (1.10–2.16)	1.32 (0.91–1.92)
>72 months	1.57 (1.21–2.04)	1.21 (0.88–1.67)

Model 1 – adjusted for age, sex. Model 2 – model 1 + smoking, diabetes mellitus, systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-density lipoprotein, antihypertensive medication use, statin use and carotid wall thickness. Model 3 – model 2+ average INR.

CI, confidence interval; INR, international normalized ratio; IPH, intraplaque haemorrhage; OR, odds ratios.